多替阿巴拉米片 说明书

Common name:

Product name: Suimeikai

All names: Trimeq, Docetabalamid, TRIUMEQ, Inbec

Indications: Suitable for the treatment of adults and adolescents over 12 years old (weight at least 40kg) infected with human immunodeficiency virus (HIV).

Usage and Dosage: For adults and adolescents (weighing at least 40kg), the recommended dosage of Dolutegra is one tablet, once a day.

Adults or adolescents whose body weight is less than 40 kg should not be given dolutea as dolutea is a fixed-dose tablet and cannot be reduced. Dolutegravir is a fixed-dose tablet and should not be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or a dose adjustment is required, separate formulations of dolutegravir, abacavir, or lamivudine may be used. In these cases, physicians should refer to the respective product information for these medicines.

If the patient misses a dose of Docetaxel, and it is more than 4 hours before the next dose, Docetaxel should be taken as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

Adverse Reactions: There are limited clinical data. The most commonly reported adverse reactions that are possibly or probably related to dolutegravir and abacalongvir/lamivudine are nausea (12%), insomnia (7%), dizziness (6%), and headache (6%). Adverse reactions (nausea, vomiting, diarrhea, pyrexia, drowsiness, rash) occur frequently in patients with abacavir hypersensitivity reactions. Therefore, patients who develop these symptoms should be carefully evaluated for the presence of this hypersensitivity reaction. Very rarely, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis have been reported and abacavir hypersensitivity cannot be excluded. In such cases, abacavir-containing medicinal products should be discontinued.